Ligand Pharmaceuticals appoints Peter Renehan and Lee Brown as VPs of Investments and Business Development; Lauren Hay moves to VP of Portfolio Strategy and Investments

Reuters03-26

Ligand Pharmaceuticals appoints Peter Renehan and Lee Brown as VPs of Investments and Business Development; Lauren Hay moves to <a href="https://laohu8.com/S/VP..UK">VP</a> of Portfolio <a href="https://laohu8.com/S/MSTR">Strategy</a> and Investments

Ligand appointed Peter Renehan as Vice President of Investments and Business Development, reporting to Paul Hadden.
Peter Renehan previously served as a Principal at Blackstone Life Sciences and previously worked in healthcare investment banking at Lazard.
Lee Brown joined as Vice President of Investments and Business Development, also reporting to Paul Hadden.
Lee Brown previously served as Global Team Leader for Healthcare at Third Bridge Group and was founder and Chief Investment Officer of Reef Knot Capital.
Lauren Hay transitioned to Vice President of Portfolio Strategy and Investments, with responsibilities that include growing and optimizing Ligand’s portfolio assets.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ligand Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603260700PRIMZONEFULLFEED9678785) on March 26, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2622851631?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-26 19:03","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2622851631","market":"fut","top_or_hot":-1,"title":"Ligand Pharmaceuticals appoints Peter Renehan and Lee Brown as VPs of Investments and Business Development; Lauren Hay moves to VP of Portfolio Strategy and Investments","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ligand Pharmaceuticals appoints Peter Renehan and Lee Brown as VPs of Investments and Business Development; Lauren Hay moves to <a href=\"https://laohu8.com/S/VP..UK\">VP</a> of Portfolio <a href=\"https://laohu8.com/S/MSTR\">Strategy</a> and Investments\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Ligand appointed Peter Renehan as Vice President of Investments and Business Development, reporting to Paul Hadden.\n        </li>\n<li>\n          Peter Renehan previously served as a Principal at <a href=\"https://laohu8.com/S/BX\">Blackstone</a> Life Sciences and previously worked in healthcare investment banking at Lazard.\n        </li>\n<li>\n          Lee Brown joined as Vice President of Investments and Business Development, also reporting to Paul Hadden.\n        </li>\n<li>\n          Lee Brown previously served as Global Team Leader for Healthcare at Third Bridge Group and was founder and Chief Investment Officer of Reef Knot Capital.\n        </li>\n<li>\n          Lauren Hay transitioned to Vice President of Portfolio <a href=\"https://laohu8.com/S/STRF\">Strategy</a> and Investments, with responsibilities that include growing and optimizing Ligand’s portfolio assets.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/LGND\">Ligand Pharmaceuticals Inc.</a> published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603260700PRIMZONEFULLFEED9678785) on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ligand Pharmaceuticals appoints Peter Renehan and Lee Brown as VPs of Investments and Business Development; Lauren Hay moves to VP of Portfolio Strategy and Investments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLigand Pharmaceuticals appoints Peter Renehan and Lee Brown as VPs of Investments and Business Development; Lauren Hay moves to VP of Portfolio Strategy and Investments\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-03-26 19:03</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Ligand Pharmaceuticals appoints Peter Renehan and Lee Brown as VPs of Investments and Business Development; Lauren Hay moves to <a href=\"https://laohu8.com/S/VP..UK\">VP</a> of Portfolio <a href=\"https://laohu8.com/S/MSTR\">Strategy</a> and Investments\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<ul>\n<li>\n          Ligand appointed Peter Renehan as Vice President of Investments and Business Development, reporting to Paul Hadden.\n        </li>\n<li>\n          Peter Renehan previously served as a Principal at <a href=\"https://laohu8.com/S/BX\">Blackstone</a> Life Sciences and previously worked in healthcare investment banking at Lazard.\n        </li>\n<li>\n          Lee Brown joined as Vice President of Investments and Business Development, also reporting to Paul Hadden.\n        </li>\n<li>\n          Lee Brown previously served as Global Team Leader for Healthcare at Third Bridge Group and was founder and Chief Investment Officer of Reef Knot Capital.\n        </li>\n<li>\n          Lauren Hay transitioned to Vice President of Portfolio <a href=\"https://laohu8.com/S/STRF\">Strategy</a> and Investments, with responsibilities that include growing and optimizing Ligand’s portfolio assets.\n        </li>\n</ul>\n<br/>\n<br/>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/LGND\">Ligand Pharmaceuticals Inc.</a> published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603260700PRIMZONEFULLFEED9678785) on March 26, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0314104364.USD","symbol_name":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260326:nNDLc7mWC1:1","article_id":"2622851631","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2622851631","pubTimestamp":1774522998,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ligand Pharmaceuticals appoints Peter Renehan and Lee Brown as VPs of Investments and Business Development; Lauren Hay moves to VP of Portfolio Strategy and Investments. Ligand appointed Peter Renehan as Vice President of Investments and Business Development, reporting to Paul Hadden.Peter Renehan previously served as a Principal at Blackstone Life Sciences and previously worked in healthcare investment banking at Lazard.Lee Brown joined as Vice President of Investments and Business Development, also reporting to Paul Hadden.Lee Brown previously served as Global Team Leader for Healthcare at Third Bridge Group and was founder and Chief Investment Officer of Reef Knot Capital.Lauren Hay transitioned to Vice President of Portfolio Strategy and Investments, with responsibilities that include growing and optimizing Ligand’s portfolio assets.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","BK4588":"碎股","LU1878469433.USD":"THREADNEEDLE (LUX) - AMERICAN SMALLER COMPANIES \"A\" (USD) ACC","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","LGND":"Ligand Pharmaceuticals Inc.","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","LU1559883803.SGD":"Aberdeen Standard SICAV I - North American Smaller Companies Fund A Acc SGD-H","IE0034390439.USD":"FTGF ROYCE US SMALLER COMPANIES \"A\" (USD) D","BK4007":"制药","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LAZ":"Lazard Class A","NDAQ":"纳斯达克OMX交易所","LU0566484027.USD":"安本美国小盘成长股","IE00BN0W2W23.USD":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (USD) ACC","IE00BN0W2V16.EUR":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (EUR) ACC","SG9999014021.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0077335932.USD":"FIDELITY AMERICAN GROWTH \"A\" INC","IE00B19Z6F94.USD":"Legg Mason Royce - US Smaller Companies A Acc USD","IE00BN0W2T93.GBP":"GUINNESS SUSTAINABLE GLOBAL EQUITY \"C\" (GBP) ACC","BK4139":"生物科技","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","SG9999014039.USD":"UNITED GLOBAL DURABLE EQUITIES (USDHDG) INC","BK4585":"ETF&股票定投概念","SG9999014005.SGD":"United Global Durable Equities Fund Acc SGD","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","BK4112":"金融交易所和数据","BK4127":"投资银行业与经纪业","SG9999014013.SGD":"United Global Durable Equities Fund Dis SGD","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC"},"translate_title":"Ligand Pharmaceuticals任命Peter Renehan和Lee Brown为投资和业务开发副总裁；劳伦·海(Lauren Hay)出任投资组合策略和投资副总裁","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LGND":0.9,"NDAQ":0.9,"LAZ":0.9},"content_text":"Ligand Pharmaceuticals appoints Peter Renehan and Lee Brown as VPs of Investments and Business Development; Lauren Hay moves to VP of Portfolio Strategy and Investments\n    \n\n\n          Ligand appointed Peter Renehan as Vice President of Investments and Business Development, reporting to Paul Hadden.\n        \n\n          Peter Renehan previously served as a Principal at Blackstone Life Sciences and previously worked in healthcare investment banking at Lazard.\n        \n\n          Lee Brown joined as Vice President of Investments and Business Development, also reporting to Paul Hadden.\n        \n\n          Lee Brown previously served as Global Team Leader for Healthcare at Third Bridge Group and was founder and Chief Investment Officer of Reef Knot Capital.\n        \n\n          Lauren Hay transitioned to Vice President of Portfolio Strategy and Investments, with responsibilities that include growing and optimizing Ligand’s portfolio assets.\n        \n\n\n\n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ligand Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603260700PRIMZONEFULLFEED9678785) on March 26, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"executive","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2622851631","isCrawlerRequest":true}